Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bromochlorosalicylanilide is a halogenated salicylanilide compound primarily used as an antifungal agent. It has also been reported to cause allergic contact dermatitis in some individuals. The drug belongs to the broader class of salicylanilides, which are known for their antimicrobial and anthelmintic properties. The primary mechanism of action for this group is the uncoupling of oxidative phosphorylation in mitochondria, thereby disrupting cellular energy production and leading to cell death[2][5]. Bromochlorosalicylanilide has also been investigated for its potential anticancer effects due to its cytotoxic activity against certain cell lines[3][6]. It is mainly used topically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bromochlorosalicylanilide.